GuytonAC. Textbook of medical physiology.
Philadelphia: WB
Saunders, 1981:
130–53.
2.
MilnorWR. Properties of cardiac tissues. In:
MountcastleVB, ed. Medical physiology. St.
Louis: CV Mosby, 1980:
978–81.
3.
PepineCJContiCR. Calcium blockers in coronary heart
disease. Mod Concepts Cardiovasc Dis1981; 50:
61–72.
4.
AntmanEMStonePHMullerJEBraunwaldE. Calcium channel blocking agents in the treatment of
cardiovascular disorders. Part 1: Basic and clinical electrophysiology
effects. Ann Intern Med1980; 93:
875–85.
5.
FleckensteinA. Specific pharmacology of calcium in myocardium, cardiac
pacemakers and vascular smooth muscle. Annu Rev
Pharmacol Toxicol1977; 17:
149–66.
6.
ZelisRFlaimSF. Calcium influx blockers and vascular smooth muscle: Do we
really understand the mechanisms?Ann Intern Med1981; 94:
124–6.
7.
BourassaMGCotePTherouxPTubauJFGenainCWatersDD. Hemodynamics and coronary flow following diltiazem
administration in anesthetized dogs and in humans.
Chest1980; 78
(suppl):224–30.
8.
YamaguchiHNagasakiFNakanishiSTakatsuFIshimuraTNishiyamaS. Effects of diltiazem on coronary artery and
hemodynamics. In: BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
204–13.
9.
TubauJFCotePBourassaMG. Systemic and coronary hemodynamic effects of intravenous
diltiazem in patients with coronary artery disease. Am J
Cardiol1980; 45: 439.
10.
KoroT. Hemodynamic study of diltiazem in exercise
tests. In: BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
190–203.
11.
WalshRBadkeFO'RourkeR. Differential effects of diltiazem and verapamil on left
ventricular performance in conscious dogs.
Circulation1979; 60 (suppl
II):15.
12.
StonePHAntmanEMMullerJEBraunwaldE. Calcium channel blocking agents in the treatment of
cardiovascular disorders. Part II: Hemodynamic effects and clinical
applications. Ann Intern Med1980; 93:
886–904.
13.
Van BreemanCSiegelB. The mechanism of α-adrenergic activation of the dog
coronary artery. Circ Res1980; 46:
426–9.
14.
OnoHHaskimotoK. Ca++ antagonism in various parameters of
cardiac function including coronary dilation with the use of nifedipine, perhexilene and
verapamil. In: WinburgMMAbikoY, eds. Ischemic myocardial and antianginal drugs.
New York: Raven Press,
1972: 77–88.
15.
HenryPO. Comparative pharmacology of calcium antagonists:
Nifedipine, verapamil and diltiazem. Am J
Cardiol1980; 46:
1047–58.
16.
FerlingJEasthopeJLAronowWS. Effects of verapamil on myocardial performance in coronary
disease. Circulation1979; 59:
313–9.
17.
KinneyELMoskowitzRMZelisR. The pharmacokinetics and pharmacology of oral diltiazem in
normal volunteers. J Clin Pharmacol1981; 21:
337–42.
18.
KandaKNokayaHOyamaY. Hemodynamic effects and pharmacokinetics of diltiazem
hydrochloride. Jpn Circulation J1978; 42: 741.
OyamaY. Hemodynamic and electrophysiological evaluations of
diltiazem hydrochloride: A clinical study. In: BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
169–88.
21.
KohnoKTakeuchiYEtohANodaK. Pharmacokinetics and bioavailability of diltiazem
(CRD-401) in dog. Arzneim Forsch1977; 27:
1424–8.
22.
MorselliPLRoveiVMitchardMDurandAGomeniRTarribandJ. Pharmacokinetics and metabolism of diltiazem in man
(observations on healthy volunteers and angina pectoris patients). In:
BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
152–67.
23.
BloedowDCPrephoRWNiesASGalJ. Serum binding of diltiazem in humans.
Pharmacologist1980; 22: 181.
24.
RoveiVGomeniRMitchardM. Pharmacokinetics and metabolism of diltiazem in
man. Acta Cardiol1980; 35:
35–45.
25.
ContiCRPepineCJCurryRC. Coronary artery spasm: An important mechanism in the
pathophysiology of ischemic heart disease. In: HarveyWP, ed. Current problems in cardiology. Vol
IV. Chicago: Year Book Medical
Publishing, 1979:
6–90.
26.
LuchiRJChahineRARaizmerAE. Coronary artery spasm. Ann
Intern Med1979; 91:
441–9.
27.
FeldmanRLWhittleJLPepineJ. Regional coronary angiographic observations during cold
stimulation. Am Heart J1982; 103: 2.
28.
MehtaJMehtaPPepineCJContiCR. Platelet function studies in coronary artery disease. VII.
Effect of aspirin and tachycardia stress on aortic and coronary venous
blood. Am J Cardiol1980; 45:
945–51.
MaseriAL'AbbateAChierchiaS. Significance of spasm in the pathogenesis of ischemic
heart disease. Am J Cardiol1979; 44:
788–92.
31.
RosenthalSJGinsburgRLambIHBaimDSSchroederJS. Efficacy of diltiazem for control of symptoms of coronary
arterial spasm. Am J Cardiol1980; 46:
1027–32.
32.
PepineCJFeldmanRLWhittleJCurryRCContiCR. Effect of diltiazem in patients with variant angina: A
randomized double-blind trial. Am Heart
J1981; 101:
719–25.
33.
PepineCJFeldmanRLContiCR. Does the initial response to diltiazem predict the
long-term response in patients with variant angina?Circulation1981; 64 (suppl
IV):935.
34.
YasueH. Effects of diltiazem on angina pectoris in comparison with
other antianginal drugs. In: BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
219–27.
35.
WatersDDTherouxPSzlachcicJDauweF. Provocative testing with ergonovine to assess the efficacy
of treatment with nifedipine, diltiazem and verapamil in variant angina.
Am J Cardiol1981; 48:
123–30.
36.
CurryRCPepineCJSabomMBContiCR. Similarities of ergonovine induced and spontaneous attacks
of variant angina. Circulation1979; 59:
307–12.
37.
KimuraEKishidaH. Treatment of variant angina with drugs: A survey of 11
cardiology institutes in Japan.
Circulation1981; 63:
844–8.
38.
PoolPESeagrenSCBonannoJASalelAFDennishGW. The treatment of exercise-inducible chronic stable angina
with diltiazem. Effect on treadmill exercise.
Chest1980; 78
(suppl):234–8.
39.
HossackKFBruceRA. Improved exercise performance in persons with stable
angina pectoris receiving diltiazem. Am J
Cardiol1981; 47:
95–101.
40.
LowRITakedaPLeeGMasonDTAvanNADeMariaAN. Effects of diltiazem-induced calcium blockade upon
exercise capacity in effort angina due to chronic coronary artery
disease. Am Heart J1981; 101:
713–8.
41.
KiowayaYNakamuraMMitsutakeATanakaSTakeshitaA. Increased exercise tolerance after oral diltiazem, a
calcium antagonist, in angina pectoris. Am Heart
J1981; 101:
143–9.
42.
TremblayGBironPProulxA. Quantitation pitfalls in comparative studies of
antianginal therapies. Am Heart J1975; 89:
521–5.
43.
OakleyGDGFoxKMDargieHJSelwynAP. Objective assessment of treatment in severe
angina. Br Med J1979; 1: 1540.
44.
KawaiCKonishiTMatsuyamaEOkazakiH. Comparative effects of three calcium antagonists
diltiazem, verapamil, and nifedipine on the sinoatrial and atrioventricular
nodes. Circulation1981; 63:
1035–42.
45.
MaedaKTakasugiTTsukanoYTanakaYShiotaK. Clinical study on the hypotensive effect of diltiazem
hydrochloride. Int J Clin Pharmacol Ther
Toxicol1981; 19:
47–55.
46.
WeishaarRAshikawaKBingRJ. Effect of diltiazem, a calcium antagonist, on myocardial
ischemia. Am J Cardiol1979; 43:
1137–43.
47.
VouhePRHeliasJGrondinCM. Myocardial protection through cold cardioplegia using
diltiazem, a calcium channel blocker. Ann Thorac
Surg1980; 30:
342–8.
48.
KilbornJRBattellocchiSLarribaudJMorselliPL. Preliminary clinical report on diltiazem in French
patients suffering from angina. In: BingRJ, ed. New drug therapy with a calcium antagonist.
Diltiazem Hakone Symposium '78. Amsterdam:
Elsevier North Holland, 1979:
129–38.
49.
SinghBNEllrodtGPeterCT. Verapamil: A review of its pharmacological properties and
therapeutic uses. Drugs1978; 15:
169–97.
50.
EbnerFDunschedeHB. Hemodynamics, therapeutic mechanism of action and clinical
findings of Adalat use based on worldwide clinical trials. In:
JateneADLichtlenPR, eds. Third International Adalat Symposium.
Amsterdam: Excerpta
Medica, 1976:
283–305.
